Cardinal Health (NYSE:CAH) Updates FY 2027 Earnings Guidance

Cardinal Health (NYSE:CAH) issued an update on its FY 2027 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 12.400-12.600 for the period, compared to the consensus EPS estimate of 12.050. The company issued revenue guidance of -.

Cardinal Health Stock Performance

NYSE CAH opened at $236.77 on Tuesday. Cardinal Health has a 52-week low of $137.75 and a 52-week high of $244.87. The company has a fifty day moving average of $227.47 and a 200-day moving average of $216.44. The company has a market capitalization of $55.45 billion, a P/E ratio of 36.20, a P/E/G ratio of 1.16 and a beta of 0.49.

Cardinal Health (NYSE:CAH) last released its earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a negative return on equity of 92.61% and a net margin of 0.62%.The business had revenue of $63.67 billion for the quarter, compared to analysts’ expectations of $65.15 billion. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, analysts forecast that Cardinal Health will post 10.77 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Wall Street Zen upgraded Cardinal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Morgan Stanley upped their price objective on shares of Cardinal Health from $245.00 to $255.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Zacks Research lowered shares of Cardinal Health from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 12th. JPMorgan Chase & Co. lowered their target price on Cardinal Health from $243.00 to $215.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Finally, William Blair initiated coverage on Cardinal Health in a research report on Tuesday, April 28th. They issued an “outperform” rating for the company. Fifteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $251.73.

Key Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Strong earnings beat: Fourth-quarter non-GAAP EPS was $2.91, $0.49 above analyst expectations. Reported non-GAAP EPS increased 40% year over year, while GAAP operating earnings and diluted EPS each rose 70%. Cardinal Health EPS and revenue results
• Positive Sentiment: Above-target fiscal 2027 outlook: Cardinal Health forecast fiscal 2027 non-GAAP EPS of $12.40 to $12.60, representing 13% to 15% growth and exceeding the company’s long-term earnings-growth target. Cardinal Health fiscal 2027 outlook
• Positive Sentiment: Capital returns remain substantial: The company completed $1.4 billion of fiscal 2026 share repurchases, received authorization for an additional $5 billion buyback, and declared a quarterly dividend of $0.5158 per share, payable October 15. Cardinal Health fiscal 2026 results and guidance
• Neutral Sentiment: Financing update: Cardinal Health terminated a five-year revolving credit facility and restructured elements of its credit facilities and financing programs. The change may improve financing flexibility, although the immediate earnings impact is unclear. Cardinal Health credit facilities restructuring
• Negative Sentiment: Revenue missed expectations: Quarterly revenue rose 6% to $63.7 billion but fell approximately $1.4 billion short of consensus estimates near $65.1 billion. With a net margin of only 0.62%, the revenue shortfall and thin profitability remain risks, particularly with CAH trading at a relatively elevated P/E ratio.

Institutional Trading of Cardinal Health

Several large investors have recently modified their holdings of the company. UMB Bank n.a. boosted its stake in shares of Cardinal Health by 2.9% during the 4th quarter. UMB Bank n.a. now owns 2,139 shares of the company’s stock worth $440,000 after acquiring an additional 60 shares during the last quarter. Regal Investment Advisors LLC raised its stake in Cardinal Health by 2.1% during the 3rd quarter. Regal Investment Advisors LLC now owns 3,109 shares of the company’s stock valued at $488,000 after purchasing an additional 65 shares during the period. Heritage Wealth Advisors lifted its holdings in shares of Cardinal Health by 31.6% in the fourth quarter. Heritage Wealth Advisors now owns 300 shares of the company’s stock worth $62,000 after buying an additional 72 shares in the last quarter. Hilltop Holdings Inc. boosted its holdings in shares of Cardinal Health by 3.5% during the 4th quarter. Hilltop Holdings Inc. now owns 2,542 shares of the company’s stock valued at $522,000 after purchasing an additional 87 shares during the last quarter. Finally, Summit Financial LLC grew its holdings in Cardinal Health by 3.0% during the 4th quarter. Summit Financial LLC now owns 2,950 shares of the company’s stock valued at $606,000 after buying an additional 87 shares in the last quarter. Institutional investors own 87.17% of the company’s stock.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.